Researchers have found in a nonrandomised pilot trial that selumetinib showed a reduction in cutaneous neurofibromatosis ...

Healx has dosed the first subject in the open-label Phase II INSPIRE-NF1 trial to assess the efficacy and safety of HLX-1502 in individuals with neurofibromatosis type 1 (NF1), a rare genetic disorder ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of ...

RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...

It’s the first treatment approved for both adults and children with NF1-related tumors. The FDA’s decision was based on positive results from a clinical trial involving 114 people (58 adults ...

Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...

Discover a study that used the Skindex-29 assessment to evaluate emotional wellbeing during selumetinib cycles.

GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of ...

Despite its impact, treatment options remain limited, with many patients facing invasive surgeries or therapies with severe side effects. A Potential Breakthrough for NF1 Patients “This trial ...

Genetic changes alone don’t fully explain tumor growth in NF-1, pointing to other contributing factors. This insight may ...

The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults and children. The drug, developed by SpringWorks Therapeutics ...

Gomekli is the first medication approved for both adult and pediatric patients with NF1-PN. The Food and Drug Administration (FDA) has approved Gomekli ™ (mirdametinib) for the treatment of ...